EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?

Chiara Corti, Carmine De Angelis, Giampaolo Bianchini, Luca Malorni, Mario Giuliano, Erika Hamilton, Rinath Jeselsohn, Komal Jhaveri, Giuseppe Curigliano, Carmen Criscitiello

Cancer Treatment Reviews · 2023-06 · 117 · 102569

DOI: 10.1016/j.ctrv.2023.102569 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2023-06. Verfasst von Chiara Corti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncolog…. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 81 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleReceptors, EstrogenFulvestrantAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

Breast cancerCERANEndocrinePROTACSERCASERD

Substanzen

Receptors, EstrogenFulvestrantErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato - Oncology (DIPO), University of Milan, Milan, Italy.
  • Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy; Laster and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
  • Department of Medical Oncology, Ospedale San Raffaele, IRCCS, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
  • "Sandro Pitigliani" Department of Medical Oncology, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy; "Sandro Pitigliani" Translational Research Unit, Hospital of Prato, Azienda USL Toscana Centro, Prato, Ita…
  • Sarah Cannon Research Institute, Nashville, TN, USA; Tennessee Oncology, PLLC, Nashville, TN, USA.
  • Breast Oncology Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; Division of Molecular and Cellular Oncology, Dana Farber Cancer Institute, Boston, MA, USA; Center for Functional Ca…

Zitieren

APA

Corti, C., De Angelis, C., Bianchini, G., Malorni, L., Giuliano, M., Hamilton, E., Jeselsohn, R., Jhaveri, K., Curigliano, G., & Criscitiello, C. (2023). Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?. Cancer Treatment Reviews, 117, 102569. https://doi.org/10.1016/j.ctrv.2023.102569

Vancouver

Corti C, De Angelis C, Bianchini G, Malorni L, Giuliano M, Hamilton E, et al. Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?. Cancer Treatment Reviews. 2023;117:102569. doi:10.1016/j.ctrv.2023.102569

BibTeX
@article{Corti2023,
  author = {Corti, Chiara and De Angelis, Carmine and Bianchini, Giampaolo and Malorni, Luca and Giuliano, Mario and Hamilton, Erika and Jeselsohn, Rinath and Jhaveri, Komal and Curigliano, Giuseppe and Criscitiello, Carmen},
  title = {Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?},
  journal = {Cancer Treatment Reviews},
  year = {2023},
  volume = {117},
  pages = {102569},
  doi = {10.1016/j.ctrv.2023.102569}
}
Kostenlos starten →